Histone deacetylase inhibitors: Multifunctional anticancer agents

Cancer Treatment Reviews

Volumn 32, Issue 3, 2006, Pages 157-165

  Liu, Tao ^a   Kuljaca, Selena ^a   Tee, Andrew ^a   Marshall, Glenn M ^a  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

Angiogenesis; Blood flow; Carcinogenesis; Histone deacetylase; Histone deacetylase inhibitor; Invasion; Migration

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANGIOGENESIS INHIBITOR; ARYLBUTYRIC ACID DERIVATIVE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RETINOIC ACID; VASCULOTROPIN; VATALANIB;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CHROMATIN STRUCTURE; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; PHENOTYPE; REVIEW; SOLID TUMOR; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; UPREGULATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL MOVEMENT; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION; VASOCONSTRICTION; VASODILATION;

EID: 33645950778     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.12.006     Document Type: Review

References (89)

1. Marks P.A., Richon V.M., Kelly W.K., Chiao J.H., and Miller T. Histone deacetylase inhibitors: Development as cancer therapy. Novartis Found Symp 259 (2004) 269-281 discussion 281-268
2. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., and Munster P.N. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65 (2005) 3815-3822
3. Nakajima H., Kim Y.B., Terano H., Yoshida M., and Horinouchi S. Fr901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241 (1998) 126-133
4. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., et al. A synthetic inhibitor of histone deacetylase, ms-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96 (1999) 4592-4597
5. Frey R.R., Wada C.K., Garland R.B., Curtin M.L., Michaelides M.R., Li J., et al. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 12 (2002) 3443-3447
6. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 91 (2004) 137-168
7. Johnstone R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
8. Mayo M.W., Denlinger C.E., Broad R.M., Yeung F., Reilly E.T., Shi Y., et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of nf-kappa b through the akt pathway. J Biol Chem 278 (2003) 18980-18989
9. Lindemann R.K., Gabrielli B., and Johnstone R.W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3 (2004) 779-788
10. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5 (1996) 245-253
11. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 101 (2004) 540-545
12. Butler L.M., Zhou X., Xu W.S., Scher H.I., Rifkind R.A., Marks P.A., et al. The histone deacetylase inhibitor saha arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99 (2002) 11700-11705
13. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K. Gene expression profiling of multiple histone deacetylase (hdac) inhibitors: Defining a common gene set produced by hdac inhibition in t24 and mda carcinoma cell lines. Mol Cancer Ther 2 (2003) 151-163
14. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 (2005) 3697-3702
15. Shi Y.J., Matson C., Lan F., Iwase S., Baba T., and Shi Y. Regulation of lsd1 histone demethylase activity by its associated factors. Mol Cell 19 (2005) 857-864
16. Wysocka J., Milne T.A., and Allis C.D. Taking lsd 1 to a new high. Cell 122 (2005) 654-658
17. Johnstone R.W., and Licht J.D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?. Cancer Cell 4 (2003) 13-18
18. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor ms-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21cip1/waf1 1. Cancer Res 63 (2003) 3637-3645
19. Subramanian C., Opipari Jr. A.W., Bian X., Castle V.P., and Kwok R.P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 (2005) 4842-4847
20. Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., Miller C., et al. Acetylation of the c terminus of ku70 by cbp and pcaf controls bax-mediated apoptosis. Mol Cell 13 (2004) 627-638
21. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 (2005) 673-678
22. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and fas/fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277 (2002) 2073-2080
23. Glick R.D., Swendeman S.L., Coffey D.C., Rifkind R.A., Marks P.A., Richon V.M., et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and cd95/cd95 ligand expression in human neuroblastoma. Cancer Res 59 (1999) 4392-4399
24. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of hdac inhibitors involves trail induction in acute myeloid leukemia cells. Nat Med 11 (2005) 77-84
25. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11 (2005) 71-76
26. Shao Y., Gao Z., Marks P.A., and Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101 (2004) 18030-18035
27. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at lys16 and trimethylation at lys20 of histone h4 is a common hallmark of human cancer. Nat Genet 37 (2005) 391-400
28. Yasui W., Oue N., Ono S., Mitani Y., Ito R., and Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci 983 (2003) 220-231
29. Song J., Noh J.H., Lee J.H., Eun J.W., Ahn Y.M., Kim S.Y., et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis 113 (2005) 264-268
30. Miller R.W., and Rubinstein J.H. Tumors in rubinstein-taybi syndrome. Am J Med Genet 56 (1995) 112-115
31. Muraoka M., Konishi M., Kikuchi-Yanoshita R., Tanaka K., Shitara N., Chong J.M., et al. P300 gene alterations in colorectal and gastric carcinomas. Oncogene 12 (1996) 1565-1569
32. Lin R.J., and Evans R.M. Acquisition of oncogenic potential by rar chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 5 (2000) 821-830
33. Wu W.S., Vallian S., Seto E., Yang W.M., Edmondson D., Roth S., et al. The growth suppressor pml represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21 (2001) 2259-2268
34. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., et al. Eto, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds msin3a through its oligomerization domain. Mol Cell Biol 21 (2001) 6470-6483
35. David G., Alland L., Hong S.H., Wong C.W., DePinho R.A., and Dejean A. Histone deacetylase associated with msin3a mediates repression by the acute promyelocytic leukemia-associated plzf protein. Oncogene 16 (1998) 2549-2556
36. Lin R.J., Nagy L., Inoue S., Shao W., Miller Jr. W.H., and Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391 (1998) 811-814
37. Borrow J., Stanton Jr. V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the creb-binding protein. Nat Genet 14 (1996) 33-41
38. Rowley J.D., Reshmi S., Sobulo O., Musvee T., Anastasi J., Raimondi S., et al. All patients with the t(11;16)(q23;p13.3) that involves mll and cbp have treatment-related hematologic disorders. Blood 90 (1997) 535-541
39. Dhordain P., Lin R.J., Quief S., Lantoine D., Kerckaert J.P., Evans R.M., et al. The laz3(bcl-6) oncoprotein recruits a smrt/msin3a/histone deacetylase containing complex to mediate transcriptional repression. Nucl Acids Res 26 (1998) 4645-4651
40. Zhu P., Martin E., Mengwasser J., Schlag P., Janssen K.P., and Gottlicher M. Induction of hdac2 expression upon loss of apc in colorectal tumorigenesis. Cancer Cell 5 (2004) 455-463
41. Cinatl Jr. J., Kotchetkov R., Blaheta R., Driever P.H., Vogel J.U., and Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma be(2)-c cells by valproic acid: Enhancement by combination with interferon-alpha. Int J Oncol 20 (2002) 97-106
42. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., et al. Histone deacetylase inhibitor laq824 both lowers expression and promotes proteasomal degradation of bcr-abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63 (2003) 5126-5135
43. Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., Yamaguchi H., et al. Histone deacetylase inhibitor laq824 down-regulates her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone b. Mol Cancer Ther 2 (2003) 971-984
44. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., et al. Modulation of p53, erbb1, erbb2, and raf-1 expression in lung cancer cells by depsipeptide fr901228. J Natl Cancer Inst 94 (2002) 504-513
45. Whetstine J.R., Ceron J., Ladd B., Dufourcq P., Reinke V., and Shi Y. Regulation of tissue-specific and extracellular matrix-related genes by a class i histone deacetylase. Mol Cell 18 (2005) 483-490
46. Toh Y., Ohga T., Endo K., Adachi E., Kusumoto H., Haraguchi M., et al. Expression of the metastasis-associated mta1 protein and its relationship to deacetylation of the histone h4 in esophageal squamous cell carcinomas. Int J Cancer 110 (2004) 362-367
47. Joseph J., Mudduluru G., Antony S., Vashistha S., Ajitkumar P., and Somasundaram K. Expression profiling of sodium butyrate (nab)-treated cells: Identification of regulation of genes related to cytokine signaling and cancer metastasis by nab. Oncogene 23 (2004) 6304-6315
48. McGarry L.C., Winnie J.N., and Ozanne B.W. Invasion of v-fos(fbr)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene 23 (2004) 5284-5292
49. Kim S.H., Ahn S., Han J.W., Lee H.W., Lee H.Y., Lee Y.W., et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315 (2004) 964-970
50. Dyer E.S., Paulsen M.T., Markwart S.M., Goh M., Livant D.L., and Ljungman M. Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int J Cancer 101 (2002) 496-499
51. Eyupoglu I.Y., Hahnen E., Buslei R., Siebzehnrubl F.A., Savaskan N.E., Luders M., et al. Suberoylanilide hydroxamic acid (saha) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93 (2005) 992-999
52. Tang X.X., Robinson M.E., Riceberg J.S., Kim D.Y., Kung B., Titus T.B., et al. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Cancer Res 10 (2004) 5837-5844
53. Coradini D., Zorzet S., Rossin R., Scarlata I., Pellizzaro C., Turrin C., et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor habut. Clin Cancer Res 10 (2004) 4822-4830
54. Kumar R., Wang R.A., and Bagheri-Yarmand R. Emerging roles of mta family members in human cancers. Semin Oncol 30 (2003) 30-37
55. Mazumdar A., Wang R.A., Mishra S.K., Adam L., Bagheri-Yarmand R., Mandal M., et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3 (2001) 30-37
56. Matsusue K., Takiguchi S., Toh Y., and Kono A. Characterization of mouse metastasis-associated gene 2: Genomic structure, nuclear localization signal, and alternative potentials as transcriptional activator and repressor. DNA Cell Biol 20 (2001) 603-611
57. Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T., et al. Kai1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268 (1995) 884-886
58. Jackson P., Marreiros A., and Russell P.J. Kai1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol 37 (2005) 530-534
59. Kim J.H., Kim B., Cai L., Choi H.J., Ohgi K.A., Tran C., et al. Transcriptional regulation of a metastasis suppressor gene by tip60 and beta-catenin complexes. Nature 434 (2005) 921-926
60. Winn R.A., Bremnes R.M., Bemis L., Franklin W.A., Miller Y.E., Cool C., et al. Gamma-catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 21 (2002) 7497-7506
61. Canes D., Chiang G.J., Billmeyer B.R., Austin C.A., Kosakowski M., Rieger-Christ K.M., et al. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer 113 (2005) 841-848
62. Rieger-Christ K.M., Ng L., Hanley R.S., Durrani O., Ma H., Yee A.S., et al. Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer 92 (2005) 2153-2159
63. Wang S., Yan-Neale Y., Fischer D., Zeremski M., Cai R., Zhu J., et al. Histone deacetylase 1 represses the small gtpase rhob expression in human nonsmall lung carcinoma cell line. Oncogene 22 (2003) 6204-6213
64. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein ezh2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
65. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., and Helin K. Ezh2 is downstream of the prb-e2f pathway, essential for proliferation and amplified in cancer. EMBO J 22 (2003) 5323-5335
66. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. Ezh2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100 (2003) 11606-11611
67. Liu L.T., Chang H.C., Chiang L.C., and Hung W.C. Histone deacetylase inhibitor up-regulates reck to inhibit mmp-2 activation and cancer cell invasion. Cancer Res 63 (2003) 3069-3072
68. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., et al. The membrane-anchored mmp inhibitor reck is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107 (2001) 789-800
69. Mori T., Kim J., Yamano T., Takeuchi H., Huang S., Umetani N., et al. Epigenetic up-regulation of c-c chemokine receptor 7 and c-x-c chemokine receptor 4 expression in melanoma cells. Cancer Res 65 (2005) 1800-1807
70. Kusters B., Leenders W.P., Wesseling P., Smits D., Verrijp K., Ruiter D.J., et al. Vascular endothelial growth factor-a(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 62 (2002) 341-345
71. Kusters B., de Waal R.M., Wesseling P., Verrijp K., Maass C., Heerschap A., et al. Differential effects of vascular endothelial growth factor a isoforms in a mouse brain metastasis model of human melanoma. Cancer Res 63 (2003) 5408-5413
72. Waltregny D., De Leval L., Glenisson W., Ly Tran S., North B.J., Bellahcene A., et al. Expression of histone deacetylase 8, a class i histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol 165 (2004) 553-564
73. Fish J.E., Matouk C.C., Rachlis A., Lin S., Tai S.C., D'Abreo C., et al. The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code. J Biol Chem 280 (2005) 24824-24838
74. Rossig L., Li H., Fisslthaler B., Urbich C., Fleming I., Forstermann U., et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91 (2002) 837-844
75. Robb G.B., Carson A.R., Tai S.C., Fish J.E., Singh S., Yamada T., et al. Post-transcriptional regulation of endothelial nitric-oxide synthase by an overlapping antisense mRNA transcript. J Biol Chem 279 (2004) 37982-37996
76. Maurice D.H., Palmer D., Tilley D.G., Dunkerley H.A., Netherton S.J., Raymond D.R., et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64 (2003) 533-546
77. Tilley D., and Maurice D.H. Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4d short form expression: Role of differential histone acetylation on camp-regulated function. Mol Pharmacol 68 (2005) 596-605
78. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7 (2001) 437-443
79. Mahon P.C., Hirota K., and Semenza G.L. Fih-1: A novel protein that interacts with hif-1alpha and vhl to mediate repression of hif-1 transcriptional activity. Genes Dev 15 (2001) 2675-2686
80. Kato H., Tamamizu-Kato S., and Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279 (2004) 41966-41974
81. Kwon H.J., Kim M.S., Kim M.J., Nakajima H., and Kim K.W. Histone deacetylase inhibitor fk228 inhibits tumor angiogenesis. Int J Cancer 97 (2002) 290-296
82. Sasakawa Y., Naoe Y., Noto T., Inoue T., Sasakawa T., Matsuo M., et al. Antitumor efficacy of fk228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 66 (2003) 897-906
83. Zgouras D., Becker U., Loitsch S., and Stein J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 316 (2004) 693-697
84. Zgouras D., Wachtershauser A., Frings D., and Stein J. Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting hif-1alpha nuclear translocation. Biochem Biophys Res Commun 300 (2003) 832-838
85. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21 (2002) 427-436
86. Michaelis M., Suhan T., Cinatl J., Driever P.H., and Cinatl Jr. J. Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25 (2004) 1795-1799
87. Qian D.Z., Wang X., Kachhap S.K., Kato Y., Wei Y., Zhang L., et al. The histone deacetylase inhibitor nvp-laq824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor ptk787/zk222584. Cancer Res 64 (2004) 6626-6634
88. Sawa H., Murakami H., Ohshima Y., Murakami M., Yamazaki I., Tamura Y., et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin a inhibit vascular endothelial growth factor (vegf) secretion from human glioblastoma cells. Brain Tumor Pathol 19 (2002) 77-81
89. Pili R., Kruszewski M.P., Hager B.W., Lantz J., and Carducci M.A. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61 (2001) 1477-1485